U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226206) titled 'A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A' on Oct. 28.
Brief Summary: This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.
Study Start Date: Jan. 30, 2026
Study Type: INTERVENTIONAL
Condition:
Hemophilia A
Intervention:
DRUG: SPK-8011QQ
Participants will receive IV SPK-8011QQ
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hoffmann-La Roche
Published by HT Digital Content Services with permission from Health Daily Digest....